AKRO News and Press, Akero Therapeutics Inc. From 05/09/23

2023-05-09 04:37:35 ET Summary Akero Therapeutics has a proof of concept in using EFX for the treatment of patients with NASH Fibrosis established in the phase 2b HARMONY study. Results from cohort D of phase 2b SYMMETRY study using EFX on top of existing GLP-1 receptor agonist th...

2023-05-07 10:05:43 ET Summary AKRO will produce phase 2b SYMMETRY data in 4Q, but phase 3 will be a few years away. I believe Madrigal's success and the far off phase 3 may dampen exuberance around SYMMETRY. However, SYMMETRY will prove its cirrhosis activity, so there may we...

2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...

2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...

2023-03-29 23:40:24 ET Summary NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million i...

2023-03-29 16:38:00 ET Akero Therapeutics said it had a positive end-of-Phase 2 meeting with the U.S. Food and Drug Administration and also discussed details of the upcoming Phase 3 trial of efruxifermin to treat nonalcoholic steatohepatitis ( NASH ). The company will start en...

The planned Phase 3 program consists of three trials, SYNCHRONY Histology , SYNCHRONY Real-World , and SYNCHRONY Outcomes to evaluate the safety and efficacy of efruxifermin (EFX) in patients with NASH SYNCHRONY Histology and SYNCHRONY ...

2023-03-22 08:13:28 ET Luminar Technologies ( LAZR ) -9% . Petco Health and Wellness ( WOOF ) -9% on Q4 earnings release . Akero Therapeutics ( AKRO ) -8% . Dermata Therapeutics ( DRMA ) -7% . Qualigen Therapeutics ( QLGN ) -7%...

2023-03-22 07:44:35 ET Liver disease drug developer 89bio ( NASDAQ: ETNB ) added ~47% on Wednesday after announcing topline data from its Phase 2b ENLIVEN trial for pegozafermin in patients with nonalcoholic steatohepatitis (NASH). The trial involved 219 patients who wer...

2023-03-17 07:07:14 ET Akero Therapeutics press release ( NASDAQ: AKRO ): Q4 GAAP EPS of -$0.49 beats by $0.31 . Akero's cash, cash equivalents and short-term marketable securities for the year ended December 31, 2022 were $351.4 million. Akero believes that its ca...